MorphoSys AG (MPSYF)
USD 73.27
(0.0%)
USD 73.27
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 477.43 Million EUR | 859.13% |
| 2022 | -62.89 Million EUR | -131.05% |
| 2021 | 202.54 Million EUR | -2.81% |
| 2020 | 208.4 Million EUR | 12043.13% |
| 2019 | -1.74 Million EUR | 96.16% |
| 2018 | -45.38 Million EUR | 41.54% |
| 2017 | -77.63 Million EUR | -3.56% |
| 2016 | -74.96 Million EUR | 17.92% |
| 2015 | -91.33 Million EUR | -180.52% |
| 2014 | -32.55 Million EUR | 55.11% |
| 2013 | -72.53 Million EUR | -74.37% |
| 2012 | -41.6 Million EUR | 23.7% |
| 2011 | -54.52 Million EUR | -23.94% |
| 2010 | -43.99 Million EUR | -6.72% |
| 2009 | -41.22 Million EUR | -2.89% |
| 2008 | -40.06 Million EUR | 17.23% |
| 2007 | -48.4 Million EUR | -1185.71% |
| 2006 | -3.76 Million EUR | 6.27% |
| 2005 | -4.01 Million EUR | 67.94% |
| 2004 | -12.53 Million EUR | -88.37% |
| 2003 | -6.65 Million EUR | -690.0% |
| 2002 | -842.08 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 129.77 Million EUR | -72.82% |
| 2023 FY | 477.43 Million EUR | 859.13% |
| 2023 Q3 | 94.67 Million EUR | -2.18% |
| 2023 Q1 | -10.66 Million EUR | 83.04% |
| 2023 Q4 | 477.43 Million EUR | 404.26% |
| 2023 Q2 | 96.79 Million EUR | 1007.35% |
| 2022 Q2 | 212.88 Million EUR | -2.91% |
| 2022 Q1 | 219.27 Million EUR | 8.26% |
| 2022 Q3 | -122.52 Million EUR | -157.56% |
| 2022 Q4 | -62.89 Million EUR | 48.67% |
| 2022 FY | -62.89 Million EUR | -131.05% |
| 2021 Q4 | 202.54 Million EUR | 171.84% |
| 2021 FY | 202.54 Million EUR | -2.81% |
| 2021 Q1 | 211.07 Million EUR | 1.28% |
| 2021 Q2 | 24.61 Million EUR | -88.34% |
| 2021 Q3 | 74.5 Million EUR | 202.67% |
| 2020 Q1 | -572.96 Million EUR | -32734.77% |
| 2020 FY | 208.4 Million EUR | 12043.13% |
| 2020 Q4 | 208.4 Million EUR | 1247.48% |
| 2020 Q3 | -18.16 Million EUR | -232.51% |
| 2020 Q2 | 13.7 Million EUR | 102.39% |
| 2019 Q3 | -15.2 Million EUR | -2.55% |
| 2019 FY | -1.74 Million EUR | 96.16% |
| 2019 Q1 | -8.16 Million EUR | 82.01% |
| 2019 Q2 | -14.82 Million EUR | -81.55% |
| 2019 Q4 | -1.74 Million EUR | 88.52% |
| 2018 Q3 | -120.9 Million EUR | -118.04% |
| 2018 Q2 | -55.45 Million EUR | 3.28% |
| 2018 Q1 | -57.32 Million EUR | 26.15% |
| 2018 Q4 | -45.38 Million EUR | 62.46% |
| 2018 FY | -45.38 Million EUR | 41.54% |
| 2017 FY | -77.63 Million EUR | -3.56% |
| 2017 Q4 | -77.63 Million EUR | 12.42% |
| 2017 Q3 | -88.64 Million EUR | -43.3% |
| 2017 Q2 | -61.86 Million EUR | 46.81% |
| 2017 Q1 | -116.29 Million EUR | -55.13% |
| 2016 Q1 | -131.59 Million EUR | -44.08% |
| 2016 Q2 | -67.35 Million EUR | 48.81% |
| 2016 Q4 | -74.96 Million EUR | -151.13% |
| 2016 Q3 | -29.85 Million EUR | 55.68% |
| 2016 FY | -74.96 Million EUR | 17.92% |
| 2015 Q1 | -33.42 Million EUR | -2.66% |
| 2015 Q2 | -55.42 Million EUR | -65.81% |
| 2015 Q3 | -26.37 Million EUR | 52.4% |
| 2015 Q4 | -91.33 Million EUR | -246.25% |
| 2015 FY | -91.33 Million EUR | -180.52% |
| 2014 Q3 | -73.73 Million EUR | -43.55% |
| 2014 FY | -32.55 Million EUR | 55.11% |
| 2014 Q2 | -51.36 Million EUR | -9.4% |
| 2014 Q4 | -32.55 Million EUR | 55.84% |
| 2014 Q1 | -46.95 Million EUR | 35.27% |
| 2013 Q3 | -104.62 Million EUR | -115.22% |
| 2013 Q4 | -72.53 Million EUR | 30.67% |
| 2013 FY | -72.53 Million EUR | -74.37% |
| 2013 Q1 | -39.75 Million EUR | 4.44% |
| 2013 Q2 | -48.61 Million EUR | -22.28% |
| 2012 Q3 | -48.81 Million EUR | -11.81% |
| 2012 Q4 | -41.6 Million EUR | 14.78% |
| 2012 FY | -41.6 Million EUR | 23.7% |
| 2012 Q1 | -38.2 Million EUR | 29.92% |
| 2012 Q2 | -43.65 Million EUR | -14.26% |
| 2011 FY | -54.52 Million EUR | -23.94% |
| 2011 Q3 | -64.33 Million EUR | -9.0% |
| 2011 Q4 | -54.52 Million EUR | 15.25% |
| 2011 Q2 | -59.02 Million EUR | -17.07% |
| 2011 Q1 | -50.41 Million EUR | -14.6% |
| 2010 Q1 | -45.31 Million EUR | -9.93% |
| 2010 FY | -43.99 Million EUR | -6.72% |
| 2010 Q3 | -41.1 Million EUR | 5.35% |
| 2010 Q4 | -43.99 Million EUR | -7.02% |
| 2010 Q2 | -43.42 Million EUR | 4.17% |
| 2009 FY | -41.22 Million EUR | -2.89% |
| 2009 Q4 | -41.22 Million EUR | 0.0% |
| 2008 FY | -40.06 Million EUR | 17.23% |
| 2007 FY | -48.4 Million EUR | -1185.71% |
| 2006 FY | -3.76 Million EUR | 6.27% |
| 2005 FY | -4.01 Million EUR | 67.94% |
| 2004 FY | -12.53 Million EUR | -88.37% |
| 2003 FY | -6.65 Million EUR | -690.0% |
| 2002 FY | -842.08 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -2928.817% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -11493.726% |
| SQZ Biotechnologies Company | -36.23 Million USD | 1417.491% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -1015.679% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 7672.854% |
| Mesoblast Limited | 55.85 Million USD | -754.721% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -51392.627% |
| Genus plc | 190.6 Million USD | -150.489% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -21253.681% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -39230.847% |
| Marizyme, Inc. | 18.56 Million USD | -2471.122% |
| ContraFect Corporation | -6.02 Million USD | 8022.875% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -70110.651% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -354501.882% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -41220.793% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -21192.721% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -8577.598% |
| MultiCell Technologies, Inc. | 90.04 USD | -530244711.195% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 65147.24% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -3587.876% |
| EV Biologics, Inc. | 1.36 Million USD | -34800.771% |
| Q BioMed Inc. | 4.06 Million USD | -11659.396% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -1462.586% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -76612.732% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -47277.677% |
| Biomind Labs Inc. | 711.4 Thousand USD | -67011.482% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | -334.804% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -3628.021% |
| Skye Bioscience, Inc. | -5.72 Million USD | 8444.694% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -55399.846% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -341401.265% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -8352.57% |
| IMV Inc. | 7.67 Million USD | -6124.25% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -2403043.041% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -21581.95% |
| GB Sciences, Inc. | 1.74 Million USD | -27223.76% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 259873.45% |
| HST Global, Inc. | 96.79 Thousand USD | -493150.987% |
| CSL Limited | 10.52 Billion USD | 95.464% |
| Halberd Corporation | 144.72 Thousand USD | -329798.514% |
| Enzolytics Inc. | 981.65 Thousand USD | -48535.411% |
| Resverlogix Corp. | 6.45 Million USD | -7300.906% |
| Affymax, Inc. | -5.59 Million USD | 8630.149% |
| SYBLEU INC | 473.71 Thousand USD | -100684.952% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 71031.545% |
| argenx SE | -2.02 Billion USD | 123.532% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -999.214% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 1115.554% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -17526.441% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 5500.873% |
| AVAX Technologies, Inc. | -5.9 Million USD | 8187.679% |
| Zenith Capital Corp. | 10.06 Thousand USD | -4743862.917% |
| Genscript Biotech Corporation | -1.06 Billion USD | 144.984% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -238101.698% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -19909.456% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -290116.601% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -688.548% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -23778.881% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 18676.906% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -132627.038% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -2254.668% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 2606456.742% |
| BioStem Technologies, Inc. | 4.47 Million USD | -10576.012% |
| ONE Bio Corp. | 9.04 Million USD | -5181.312% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -237128.789% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 36445323.511% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -231419.432% |
| Agentix Corp. | 37.63 Thousand USD | -1268621.076% |
| LadRx Corporation | -2.03 Million USD | 23544.129% |
| Cell Source, Inc. | 9.23 Million USD | -5071.511% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 2339537.613% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -75066.441% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -75066.441% |
| NovAccess Global Inc. | 2.17 Million USD | -21816.002% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -6652.006% |
| Itoco Inc. | 228.3 Thousand USD | -209020.443% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -350981.652% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -9531.479% |
| Kadimastem Ltd | -253.1 Thousand USD | 188732.42% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -118708.913% |
| CytoDyn Inc. | 20.26 Million USD | -2256.295% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 73791819.938% |
| Mobile Lads Corp. | 484.23 Thousand USD | -98495.803% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 5151318.32% |
| Qrons Inc. | 351.42 Thousand USD | -135755.363% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -6095.592% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 191363.692% |
| Rebus Holdings, Inc. | 305 Thousand USD | -156435.222% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -10611.915% |
| International Stem Cell Corporation | 2.59 Million USD | -18333.684% |
| Bioxytran, Inc. | 1.89 Million USD | -25042.393% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -764856.705% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -21791.532% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -13803.099% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -5482.046% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -61694.991% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 38294.594% |
| Neutra Corp. | 52.18 Thousand USD | -914749.346% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 19281.697% |
| PureTech Health plc | -167.19 Million USD | 385.551% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 195043.582% |
| IXICO plc | -4.44 Million USD | 10841.885% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -3511.714% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -770.417% |
| CSL Limited | 10.52 Billion USD | 95.464% |
| Cellectis S.A. | -43.81 Million USD | 1189.559% |